Biotron Limited (BITRF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Sydney, NSW, Australia. The current CEO is Michelle Miller GCertAppFin.
BITRF has IPO date of 2013-03-22, listed on the Other OTC, a market capitalization of $29.15M.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
